Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.

@article{Guerrouahen2010DasatinibIT,
  title={Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.},
  author={Bella S. Guerrouahen and Muneyoshi Futami and Christos Vaklavas and Jukka A Kanerva and Zakary L. Whichard and Kenechi Nwawka and Elisabeth G. Blanchard and Francis Y. F. Lee and Lisa J. Robinson and Robert J. Arceci and Steven M. Kornblau and Eric Wieder and Yvon E. Cayre and Seth J Corey},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2010},
  volume={16 4},
  pages={1149-58}
}
PURPOSE Dasatinib is a dual Src/Abl inhibitor recently approved for Bcr-Abl+ leukemias with resistance or intolerance to prior therapy. Because Src kinases contribute to multiple blood cell functions by triggering a variety of signaling pathways, we hypothesized that their molecular targeting might lead to growth inhibition in acute myeloid leukemia (AML). EXPERIMENTAL DESIGN We studied growth factor-dependent and growth factor-independent leukemic cell lines, including three cell lines… CONTINUE READING
25 Extracted Citations
45 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 25 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 45 references

Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indoliClin Cancer Res

  • E Kulimova, E Oelmann, G Bisping
  • Mol Cancer Ther 2006;5:3105–12
  • 2010

Phase I doseescalation study of the SRC and multi-kinase inhibitopr BMS-354825 in patients with GISTand other solid tumors

  • TR Evans, JA Morgan, AD van den Abbeele
  • J Clin Oncol 2005;23: 3034A. Clin Cancer Res;
  • 2010
1 Excerpt

High throughout sequenceanalysis of the tyrosine kinome in acute myeloid leukemia

  • LoriauxMM, LevineRL, JW Tyner
  • Blood
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…